Keyword Connections

pegylated

Journals

9

1 The Journal of Chemical Physics

2 Langmuir : the ACS journal of surfaces and colloids

3 pakistan journal of pharmaceutical sciences

4 the journal of physical chemistry b

5 jpma the journal of the pakistan medical association

6 methods in molecular biology (clifton, nj)

7 hematology/oncology and stem cell therapy

8 Asian Pacific journal of cancer prevention : APJCP

9 Hellenic journal of nuclear medicine

Research Groups

0

No Research Group Connected

Bibliographies

64

1 Molecular-Level "Observations" of the Behavior of Gold Nanoparticles in Aqueous Solution and Interacting with a Lipid Bilayer Membrane.

2 The Composition of the Mobile Phase Affects the Dynamic Chiral Recognition of Drug Molecules by the Chiral Stationary Phase.

3 Aromatic Polyamide Reverse-Osmosis Membrane: An Atomistic Molecular Dynamics Simulation.

4 Simulated Permeation and Characterization of PEGylated Gold Nanoparticles in a Lipid Bilayer System.

5 Trends and Analysis of Cancer Incidence for Common Male and Female Cancers in the Population of Punjab Province of Pakistan during 1984 to 2014.

6 Surface-functionalized nanoparticle permeation triggers lipid displacement and water and ion leakage.

7 Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.

8 Communication: A tractable design for a thermal transistor.

9 Preparation of (99m)Tc-labelled methotraxate by a direct labeling technique as a potential diagnostic agent for breast cancer and preliminary clinical results.

10 In house development of (99m)Tc-Rhenium sulfide colloidal nanoparticles for sentinel lymph node detection.

11 Synthesis, characterization and bioevaluation of technetium-99m labeled N-(2-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose as a tumor imaging agent.

12 Development of 99mTc-5-fluorouracil as a potential tumor diagnostic agent.

13 Nanoparticle permeation induces water penetration, ion transport, and lipid flip-flop.

14 Communication: Thermal rectification in liquids by manipulating the solid-liquid interface.

15 Note: the role of external electric fields in enhancing ion mobility, drift velocity, and drift-diffusion rates in aqueous electrolyte solutions [J. Chem. Phys. 134, 114504 (2011)].

16 The role of external electric fields in enhancing ion mobility, drift velocity, and drift-diffusion rates in aqueous electrolyte solutions.

17 Influence of hydrophilic surface specificity on the structural properties of confined water.

18 Post mastectomy adjuvant radiotherapy in breast cancer: a comparision of three hypofractionated protocols.

19 A PEGylated alternating copolymer with oxidation-sensitive phenylboronic ester pendants for anticancer drug delivery.

20 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

21 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

22 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

23 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

24 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

25 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

26 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

27 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

28 Facile fabrication of glycosylated and PEGylated carbon nanotubes through the combination of mussel inspired chemistry and surface-initiated ATRP

29 Multi-mycotoxins analysis in liquid milk by UHPLC-Q-Exactive HRMS after magnetic solid-phase extraction based on PEGylated multi-walled carbon nanotubes.

30 Antiplatelet effect of differentially charged PEGylated lipid-polymer nanoparticles.

31 Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice

32 Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy

33 Biophysical and biological characterization of PEGylated recombinant human endostatin.

34 A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.

35 Gender differences in the pharmacological actions of pegylated glucagon-like peptide-1 on endothelial progenitor cells and angiogenic precursor cells in a combination of metabolic disorders and lung emphysema

36 Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis.

37 KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.

38 Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks.

39 Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.

40 Nanoscale characterization of PEGylated phospholipid coatings formed by spray drying on silica microparticles.

41 Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)

42 mixed pegylated surfactant modifying system decrease the accelerated blood clearance phenomenon of nanoemulsions in rats

43 pegylated amine-functionalized poly(ε-caprolactone) for the delivery of plasmid dna

44 lichen planus induced by pegylated interferon alfa-2a therapy in a patient monitored for delta hepatitis

45 pegylated liposomal doxorubicin-induced acute transient encephalopathy in a patient with breast cancer: a case report

46 pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis c after liver transplantation: from a canadian experience to recommendations for therapy

47 the accelerated blood clearance phenomenon of pegylated nanoemulsion upon cross administration with nanoemulsions modified with polyglycerin

48 boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis c virus genotype 1 in hiv–hcv co-infected patients: final results of the spanish boc hiv–hcv study

49 hesperetin conjugated pegylated gold nanoparticles exploring the potential role in anti-inflammation and anti-proliferation during diethylnitrosamine-induced hepatocarcinogenesis in rats

50 acid-sensitive sheddable pegylated plga nanoparticles increase the delivery of tnf-α sirna in chronic inflammation sites

51 retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy

52 response to pegylated interferon plus ribavirin in patients with hepatitis c virus genotype 6a infection from guangdong and guangxi province of china

53 pegylated apoptotic protein-loaded plga microspheres for cancer therapy

54 very-low-dose pegylated interferon α2a plus ribavirin therapy for advanced liver cirrhosis type c: a possible therapeutic alternative without splenic intervention

55 improvement of pharmacokinetic and antitumor activity of layered double hydroxide nanoparticles by coating with pegylated phospholipid membrane

56 efficacy and safety of a novel pegylated interferon alpha-2a in egyptian patients with genotype 4 chronic hepatitis c

57 renal-targeted delivery of triptolide by entrapment in pegylated trx-20-modified liposomes

58 stereocomplex-reinforced pegylated polylactide micelle for optimized drug delivery

59 effective delivery of pegylated sirna-containing lipoplexes to extraperitoneal tumours following intraperitoneal administration

60 Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial

61 Positional Isomers of Monopegylated Interferon α-2a: Isolation, Characterization, and Biological Activity

62 Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C

63 Telaprevir for HIV/Hepatitis C Virus–Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

64 Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas.